127 related articles for article (PubMed ID: 33533020)
1. Importance of antibody isotypes in antitumor immunity by monocytes and complement using human-immune tumor models.
Lara S; Anania JC; Virtanen A; Stenhammar V; Kleinau S
Eur J Immunol; 2021 May; 51(5):1218-1233. PubMed ID: 33533020
[TBL] [Abstract][Full Text] [Related]
2. Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
Lara S; Heilig J; Virtanen A; Kleinau S
BMC Cancer; 2022 Jun; 22(1):678. PubMed ID: 35725455
[TBL] [Abstract][Full Text] [Related]
3. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
4. Complement and cellular cytotoxicity in antibody therapy of cancer.
Wang SY; Weiner G
Expert Opin Biol Ther; 2008 Jun; 8(6):759-68. PubMed ID: 18476787
[TBL] [Abstract][Full Text] [Related]
5. Biological activity in the human system of isotype variants of oligosaccharide-Y-specific murine monoclonal antibodies.
Scholz D; Lubeck M; Loibner H; McDonald-Smith J; Kimoto Y; Koprowski H; Steplewski Z
Cancer Immunol Immunother; 1991; 33(3):153-7. PubMed ID: 2044080
[TBL] [Abstract][Full Text] [Related]
6. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.
Meyer S; Leusen JH; Boross P
MAbs; 2014; 6(5):1133-44. PubMed ID: 25517299
[TBL] [Abstract][Full Text] [Related]
7. Impact of Fc receptors and host characteristics on myeloid phagocytic response to rituximab-treated 3D-cultured B-cell lymphoma.
Kleinau S
Immunother Adv; 2023; 3(1):ltad025. PubMed ID: 38020313
[TBL] [Abstract][Full Text] [Related]
8. Cytolytic activity of murine anti-dog lymphoma monoclonal antibodies with canine effector cells and complement.
Rosales C; Jeglum KA; Obrocka M; Steplewski Z
Cell Immunol; 1988 Sep; 115(2):420-8. PubMed ID: 3409330
[TBL] [Abstract][Full Text] [Related]
9. Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies.
Lohse S; Peipp M; Beyer T; Valerius T; Dechant M
Arch Immunol Ther Exp (Warsz); 2010 Aug; 58(4):303-12. PubMed ID: 20508996
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
11. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
Barth MJ; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2015 Oct; 21(19):4391-7. PubMed ID: 25964296
[TBL] [Abstract][Full Text] [Related]
12. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
van Meerten T; van Rijn RS; Hol S; Hagenbeek A; Ebeling SB
Clin Cancer Res; 2006 Jul; 12(13):4027-35. PubMed ID: 16818702
[TBL] [Abstract][Full Text] [Related]
13. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
Harjunpää A; Junnikkala S; Meri S
Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions.
Miller ML; Finn OJ
Methods Enzymol; 2020; 632():431-456. PubMed ID: 32000909
[TBL] [Abstract][Full Text] [Related]
15. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
16. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Weng WK; Levy R
Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
[TBL] [Abstract][Full Text] [Related]
17. Complement in antibody-based tumor therapy.
Derer S; Beurskens FJ; Rosner T; Peipp M; Valerius T
Crit Rev Immunol; 2014; 34(3):199-214. PubMed ID: 24941073
[TBL] [Abstract][Full Text] [Related]
18. The complement system in cancer: Ambivalence between tumour destruction and promotion.
Mamidi S; Höne S; Kirschfink M
Immunobiology; 2017 Jan; 222(1):45-54. PubMed ID: 26686908
[TBL] [Abstract][Full Text] [Related]
19. slan
Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
[TBL] [Abstract][Full Text] [Related]
20. A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent
Ponath P; Menezes D; Pan C; Chen B; Oyasu M; Strachan D; LeBlanc H; Sun H; Wang XT; Rangan VS; Deshpande S; Cristea S; Park KS; Sage J; Cardarelli PM
Clin Cancer Res; 2018 Oct; 24(20):5178-5189. PubMed ID: 30021910
[No Abstract] [Full Text] [Related]
[Next] [New Search]
